E4NA Stock Chart & Stats
€0.04
€0.00(0.00%)
At close: 4:00 PM EDT
€0.04
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.04 - €0.06
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€46.47M
Enterprise Value€60.24
Total Cash (Recent Filing)€14.35M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta1.19
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,208,851,800
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.55
Price to Book (P/B)5.47
Price to Sales (P/S)806.87
P/FCF Ratio-14.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageNear-zero debt materially reduces financial risk for an R&D‑intensive biotech. Over the next 2–6 months this conservatism lowers interest burdens and bankruptcy risk, preserving optionality to fund trials via equity or partnerships without immediate debt servicing constraints.
Stronger Equity BaseA materially larger equity base increases the company’s capacity to absorb ongoing losses and finance near-term clinical work. This bolsters the balance sheet for the coming months, reducing immediate refinancing pressure and supporting program continuity during early clinical progress.
Cell‑therapy Pipeline FocusArovella’s focus on engineered immune cell platforms aligns with durable oncology industry growth and demand for cell therapies. Structural tailwinds and platform scalability increase long-term commercial potential, aiding partnership and licensing opportunities beyond short-term funding cycles.
Bears Say
Chronic Cash BurnSustained negative operating and free cash flow means the business cannot self-fund R&D or trials and remains dependent on external financing. Over a 2–6 month horizon this increases dilution and execution risk if financing windows close or terms worsen.
Sustained Operating LossesPersistent large operating losses indicate the company is not yet commercialized and must burn capital to progress programs. Continued negative margins constrain reinvestment and raise the likelihood of program slowdowns or tougher capital raises in the medium term.
Very Low, Volatile RevenueRevenue instability and a sharp year‑over‑year decline increase dependence on fundraising rather than operations. This undermines predictability of cash runway and makes it harder to scale programs or attract stable partnerships over coming months without clear revenue improvements.
Arovella Therapeutics Limited News
E4NA FAQ
What was Arovella Therapeutics Limited’s price range in the past 12 months?
Arovella Therapeutics Limited lowest stock price was €0.04 and its highest was €0.06 in the past 12 months.
What is Arovella Therapeutics Limited’s market cap?
Arovella Therapeutics Limited’s market cap is €46.47M.
When is Arovella Therapeutics Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Arovella Therapeutics Limited’s earnings last quarter?
Currently, no data Available
Is Arovella Therapeutics Limited overvalued?
According to Wall Street analysts Arovella Therapeutics Limited’s price is currently Overvalued.
Does Arovella Therapeutics Limited pay dividends?
Arovella Therapeutics Limited does not currently pay dividends.
What is Arovella Therapeutics Limited’s EPS estimate?
Arovella Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Arovella Therapeutics Limited have?
Arovella Therapeutics Limited has 1,208,851,800 shares outstanding.
What happened to Arovella Therapeutics Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Arovella Therapeutics Limited?
Currently, no hedge funds are holding shares in DE:E4NA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arovella Therapeutics Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
DE:E4NA Sentiment 86%
Sector Average 61%
Sector Average 61%
Insider Transactions
Bought Shares
Worth €8.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-56.31%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
60.08%
Trailing 12-Months
Company Description
Arovella Therapeutics Limited
Arovella Therapeutics Limited, an Australian biotechnology firm, is dedicated to developing therapeutic solutions for oncology and central nervous system afflictions, operating both domestically and internationally. Its pipeline features several key assets, including ZolpiMist, an oral spray formulation of zolpidem tartrate for the treatment of short-term insomnia, commercially known by brands such as Ambien or Stilnox. The company is also advancing an invariant natural killer T (iNKT) cell therapy platform specifically designed to target blood cancers. Furthermore, Arovella employs OroMist, an oro-mucosal technology enabling the delivery of various drug classes through absorption in the oral cavity via the cheeks, gums, tongue, or mouth floor, and is developing Anagrelide for cancer treatment. Beyond these, the company is engaged in creating oral sprays to address conditions like migraine headaches, motion sickness, and drug-resistant epilepsy. Arovella maintains a research collaboration agreement with Imperial College London. Established in 1999 and based in Osborne Park, Australia, the company was formerly known as Suda Pharmaceuticals Ltd before rebranding to Arovella Therapeutics Limited in October 2021.
Technical Analysis
Imugene
―
Immutep Ltd
―
Prescient Therapeutics Limited
―
Radiopharm Theranostics Limited
―
Recce Pharmaceuticals Ltd.
―